Complete Thursday Morning Update On Nasdaq Biotech (GNPX)
National Securities Provides $7.00 Price Target (MarketBeat)
There have been some serious eyes on GNPX this week. Why? Let me show you...
On Tuesday, the company dropped this major press release:
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
The company then followed up on Wednesday with this huge news:
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
Both of these news releases have brought serious attention to GNPX this week and could become catalyst sparks towards a potential breakout in the near term.
If GNPX is able to break through potential $4.00 resistance that it battled this week, it could look to advance further towards previous highs.
Remember, GNPX has been a previous champ and has demonstrated the ability to make strong vertical surges in short periods of time.
If you've yet to read my initial report below, do so now and get GNPX pulled up quickly.
There's no time to waste this morning as your past champ NASDAQ biotech profile Genprex, Inc. (GNPX) could be breakout bound.
I've brought this profile to you on several occasions over the past couple years only to watch it go on major runs.
Back on 2/11/20, GNPX was alerted at approximately $1.61 and ran to a 2/25/20 high of $7.03 for an approximate 336% move.
I followed up with GNPX when I brought it to your attention on 7/22/20 and watched it run from an open of $3.45 to 7/23/20's high of $4.50 for a two day surge of approximately 30%.
Finally, I brought it back on 12/22/20 when it opened at $4.10 before reaching a $7.72 high on February 8th of this year for an approximately 88% move.
Genprex, Inc. (GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes.
Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.
GNPX's MAJOR COMPETITIVE ADVANTAGES
(From The Company Presentation)
GENE THERAPY PLATFORM. Our non-viral Oncoprex® nanoparticle delivery system is designed to deliver a variety of therapeutic genes to fight cancer. Data indicate that our lead drug candidate, REQORSA™ immunogene therapy, may be combined with a number of approved cancer drugs, and that it may be effective against many types of cancer, including non-small cell lung cancer, glioblastoma, head and neck cancer, breast cancer (including triple negative breast cancer), renal cell carcinoma, and soft tissue carcinoma.
FIRST IN HUMANS. We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy to be used for cancer in humans.
LARGE MARKETS AND UNMET NEED IN CANCER & DIABETES. Our initial disease indication is non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer deaths worldwide. NSCLC constitutes approximately 84% of lung cancers, and the projected market size of lung cancer therapeutics is expected to grow to $26.3Bn by 2023. We are also developing a separate therapy for diabetes, with a projected $78.2Bn market by the end of 2026.
REQORSA™ CAN BE COMBINED WITH AND MAY IMPROVE THE BENEFITS OF TOP-SELLING CANCER DRUGS. REQORSA is synergistic with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including Tagrisso, and with checkpoint inhibitors, including Keytruda. Tagrisso, with sales of more than $3Bn in 2019, is AstraZeneca’s largest selling drug. Keytruda, with sales of more than $11Bn in 2019, is Merck’s largest selling drug. Data show that combining REQORSA with Tagrisso or Keytruda achieves more favorable results than either drug alone.
FDA FAST TRACK DESIGNATION for use of REQORSA, combined with Astra Zeneca’s Tagrisso, in late stage lung cancer patients whose disease progressed after treatment with Tagrisso. Nearly all patients receiving Tagrisso experience disease progression. According to AstraZeneca’s data, the median time to progression is about 18 months.
DEMONSTRATED CLINICAL ACHIEVEMENT. REQORSA has been tested in more than 50 patients over two Phase 1 clinical trials and a portion of a Phase 2 clinical trial showing a favorable safety profile and evidence of efficacy in lung cancer.
INITIATIATING TWO CLINICAL TRIALS IN LUNG CANCER IN 2021. We plan to initiate a clinical trial of REQORSA combined with Tagrisso and a clinical trial of REQORSA combined with Keytruda in late-stage lung cancer patients in 2021.
WORLD CLASS ACADEMIC PARTNERS. Our cancer therapies were invented and developed at The University of Texas MD Anderson Cancer Center. Our diabetes therapy was invented and developed at the University of Pittsburgh.
EXPANDING OUR PIPELINE. We are constantly working to add to our pipeline of new drugs, drug combinations and disease indications through a robust preclinical research program at MD Anderson, and by actively exploring in-licensing and other acquisition opportunities.
STRONG BALANCE SHEET. With a strong balance sheet, we are well positioned to advance our programs.